36172-55-1

Usage

Uses

Used in Pharmaceutical Industry:
(E)-N,N-DiMethyl-N'-(3-Methylpyridin-2-yl)forMiMidaMide is used as a key component in drug discovery and development for its potential biological and pharmacological activities. It plays a crucial role in the creation of new drugs that can target various diseases and conditions.
Used in Chemical Research:
In the field of chemical research, (E)-N,N-DiMethyl-N'-(3-Methylpyridin-2-yl)forMiMidaMide is used as a reagent, contributing to the advancement of scientific knowledge and the development of new chemical processes and products.
Used in Organic Synthesis:
(E)-N,N-DiMethyl-N'-(3-Methylpyridin-2-yl)forMiMidaMide is also utilized in organic synthesis, where it serves as a building block for the creation of more complex molecules with specific properties and applications.

Upstream product

• 1603-40-3 3-methylpyridin-2-ylamine 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 

Downstream Products

• 114604-81-8 3-(4-hydroxybenzoyl)-8-methylimidazo<1,2-a>pyridine 
• 4931-18-4 8-methyl-[1,2,4]triazolo[1,5-a]pyridine 
• 114604-52-3 3-{4-[(dibutylamino)propoxy]benzoyl}-8-methylimidazo[1,2-a]pyridine 

Relevant academic research and scientific papers

Investigations on substituted (2-aminothiazol-5-yl)(imidazo[1,2-a]pyridin-3-yl)methanones for the treatment of Alzheimer's disease

Alzheimer's disease (AD) is a neurodegenerative disease majorly affecting old age populations. Various factors that affect the progression of the disease include, amyloid plaque formation, neurofibrillary tangles, inflammation, oxidative stress, etc. Here

1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors with a Novel Monodentate Binding Interaction

Herein we describe the identification of 4-{[1,2,4]triazolo[1,5-a]pyridin-5-yl}benzonitrile-based inhibitors of the hypoxia-inducible factor prolylhydroxylase domain-1 (PHD-1) enzyme. These inhibitors were shown to possess a novel binding mode by X-ray crystallography, in which the triazolo N1 atom coordinates in a hitherto unreported monodentate interaction with the active site Fe2+ ion, while the benzonitrile group accepts a hydrogen-bonding interaction from the side chain residue of Asn315. Further optimization led to potent PHD-1 inhibitors with good physicochemical and pharmacokinetic properties.

One-pot synthesis of new imidazo[1,2-a]pyridine and midazo[1,2-a]pyrimidine derivatives

New imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine derivatives were easily obtained by an one-pot synthesis that implies the reaction of the corresponding 2-aminoheterocycles with N,N-dimethylformamide dimethylacetal (DMFDMA), followed by the reactio

Synthesis of (aryloxy)alkylamines. 2. Novel imidazo-fused heterocycles with calcium channel blocking and local anesthetic activity

A series of imidazo-fused heterocycles substituted with an (aryloxy)alkylamine side chain were prepared as modifications to butoprozine (I) and found to possess calcium channel blocking activity similar in potency to that of bepridil in trachea smooth mus